RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC.

Wang, Qian; Yu, Tao; Ke, Zi-Hao; Wang, Fu-Feng; Yin, Jia-Ni; Shao, Yang; Lu, Kai-Hua

Wang, Qian; Yu, Tao; Ke, Zi-Hao; Wang, Fu-Feng; Yin, Jia-Ni; Shao, Yang; Lu, Kai-Hua.

Afiliação

Wang Q; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yu T; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Ke ZH; Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wang FF; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Yin JN; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Shao Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Lu KH; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.

Front Oncol ; 13: 1172728, 2023.

Article em En | MEDLINE | ID: mdl-37441425

Palavras-chave

RB1; cell cycle; chromosomal instability; combination immunotherapy; immune checkpoint inhibitors; next-generation sequencing; non-small cell lung cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google